ClinicalTrials.gg
CompletedNCT04655027Updated Apr 22, 2024Results posted

A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)

A Phase 4 interventional study of Roxadustat and rHuEPO in Anemia of Chronic Kidney Disease, sponsored by AstraZeneca. Completed at 8 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-04-22.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing roxadustat in Renal Insufficiency, Chronic — none open to participants now, 1 under way, 1 of them phase 3. roxadustat · Renal Insufficiency, Chronic.

Enrollment
17th of 19
25 · median 161
Started
2021
the only one that year
Phase 4
2 of 19
none open now
Registered
16th of 19
by date
Lead sponsor
1 of 19
AstraZeneca

Among the 19 studies testing roxadustat in Renal Insufficiency, Chronic, this one is the 17th largest by enrollment, is the only one that started in 2021, is one of 2 in phase 4, and was the 16th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

None of the 19 studies testing roxadustat in Renal Insufficiency, Chronic is open now. The open studies under Renal Insufficiency, Chronic, anywhere →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing roxadustat in Renal Insufficiency, Chronic as a file.
02

Study summary

This is a Phase IV, randomized, active-controlled, open-label, parallel design, multicenter prospective study to evaluate the effect of roxadustat versus rHuEPO treatment on the gastrointestinal (GI) iron absorption in patients with anemia of Stage 4 and Stage 5 CKD.

Read the detailed description

This is an open-label study, after eligibility confirmation patients will be randomized in a 1:1 ratio to either roxadustat or rHuEPO arms for 2 weeks.

The study will enroll eligible dialysis and non-dialysis patients ≥18 years of age, who have anemia of CKD, and are either dialysis-dependent (DD) and on a stable dose of rHuEPO within 4 weeks prior to screening, or are non-dialysis-dependent (NDD) and are being treated with rHuEPO (ie, on a stable dose of rHuEPO within 4 weeks prior to screening), or are rHuEPO -naïve at the time of screening.

Each patient will be contacted before the first Screening Visit (Visit 1) for the symptoms of coronavirus disease of 2019 (COVID-19) and for any contact with COVID-19 positive person within the past 14 days.

For each patient, the duration of participation in the study will be approximately 8 to 9 weeks divided into 3 periods: Screening Period (approximately 2-3 weeks); Treatment Period (2 weeks) and Post-Treatment Follow-up Period (4 weeks).

03

Conditions studied

  • Anemia of Chronic Kidney Disease

Keywords

  • Recombinant Human Erythropoietin
  • Roxadustat
  • Coronavirus disease of 2019
  • Chronic kidney disease
  • Anemia
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

• Provision of signed and dated, written informed consent form (ICF) prior to any mandatory study specific procedures, sampling, and analyses.

Type of patient and disease characteristics

At Visit 1 prior to screening

Dialysis patients:

  • Patients receiving hemodialysis (HD) or peritoneal dialysis (PD) for treatment of end-stage renal disease (ESRD) for at least 12 weeks. Patients treated with HD must have access consisting of an arteriovenous (AV) fistula, AV graft, or tunneled (permanent) catheter. Patients on PD must have a functioning PD catheter in place.
  • Hemodialysis patients should be on 3x/week dialysis with evidence of achievement of adequate dialysis as defined by standardized Kt/V ≥2.1 in HD, and total (renal + PD) weekly Kt/V ≥1.7 in PD documented twice during the 16 weeks preceding screening for the study.
  • Patients should be on a stable rHuEPO dose as defined by change in rHuEPO dose, not exceeding 20% within 4 weeks prior to screening.

Non-dialysis patients:

  • Patients with estimated (eGFR) \<30 mL/minute/1.73 m\^2, corresponding to Stage 4 or Stage 5 CKD according to the Kidney Disease Outcomes Quality Initiative (KDOQI), and not receiving dialysis.
  • Patients should either be on a stable dose of rHuEPO for 4 weeks before screening or be rHuEPO-naïve.

Dialysis and non-dialysis patients:

  • Patients agree not to take any new traditional Chinese medicine (TCM) and not to change, dose, schedule or brand of any TCM from beginning of the Screening Period through the end of the Follow-up Period.

At Visit 1 (screening)

  • Ferritin ≥50 ng/mL and transferrin saturation (TSAT) ≥15% in non-dialysis patients
  • Ferritin ≥100 ng/mL and TSAT ≥20% in dialysis patients.
  • Dry body weight should be 45 to 100 kg.

During the Screening Period:

  • Dialysis patients must have a mean level of ≥ 9 to ≤ 12 g/dL based on the mean of the 2 most recent central laboratory Hb values within 0.50 g/dL on 2 assays taken at least 7 days apart during the Screening Period.
  • Non-dialysis patients must have a mean Hb level of ≥ 9 to ≤ 12 g/dL for rHuEPO-user patients and ≥ 7 and ≤ 10 g/dL for rHuEPO-naïve patients, based on the mean of the 2 most recent central laboratory Hb values within 0.50 g/dL on 2 assays taken at least 7 days apart during the Screening Period.

At Visit 1 Screening:

  • Serum folate level ≥ lower limit of normal (LLN).
  • Serum vitamin B12 level ≥ LLN.
  • (ALT) or aspartate aminotransferase (AST) ≤ 3 x and total (TBL) ≤ 1.5 x ULN.
  • Negative test results on the swab test to rule out active COVID-19 infection. If according to site procedures the test for COVID-19 infection cannot be performed at the first Screening Visit, the test should be performed as soon as possible thereafter but must be performed before the patient returns for the next study visit. Any patient who has had confirmed COVID-19 infection in the past, has fully recovered from symptoms at least 14 days prior to Screening, and has a negative swab test result for COVID-19 infection at Screening, may be included in the study.

Reproduction:

  • Serum pregnancy test should be negative for female of at the start of the Screening Period.
  • Female patients of childbearing potential and male patients (non-surgically sterile) with a female partner of childbearing potential must, if not practicing complete sexual abstinence, agree to practice a dual method of .

Contraceptive methods must be practiced upon being randomized to the study and through 7 days after the last dose of study treatment. Male patients must not donate or bank sperm during this same time period.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Class III or IV congestive heart failure (CHF) at screening.
  • Acute coronary syndrome, stroke, seizure or a thrombotic/thromboembolic event (eg, deep vein thrombosis or pulmonary embolism) within 12 weeks prior to randomization.
  • History of severe, chronic, end-stage, or uncontrolled liver disease with 3 x , or AST > 3 × ULN, or total > 1.5 × ULN.
  • Known hereditary hematologic disease such as thalassemia, sickle cell anemia, a history of pure red-cell aplasia or other known causes for anemia other than CKD.
  • Known and untreated retinal vein occlusion or known and untreated proliferative diabetic retinopathy.
  • Systolic BP ≥160 mmHg or diastolic BP ≥95 mmHg (confirmed by repeated measurement), within 2 weeks prior to randomization. Patients may be rescreened once BP is controlled.
  • History of prostate cancer, breast cancer, renal cell carcinoma or any other , except the following: cancers determined to be cured or in remission for ≥5 years; curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps.
  • Chronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythromatosus (SLE), ankylosing spondylitis, psoriatic arthritis or active inflammatory bowel disease that is determined to be the principal cause of anemia.
  • Known hemosiderosis, hemochromatosis or hypercoagulable condition.
  • Any prior organ transplant or a scheduled organ transplantation date.
  • Any current condition leading to active significant blood loss.
  • Known allergy to the study treatment or any of its ingredients.
  • Any medical condition, including active, infection, that in the opinion of the Investigator or Sponsor may pose a safety risk to a patient in this study, which may confound safety or efficacy assessment or may interfere with study participation.
  • Intolerance of oral iron in the past as defined by stomach upset, nausea, vomiting, or diarrhea.
  • Active GI bleed.
  • Hospitalizations within the 12 weeks preceding study randomization for GI bleeding or Congestive heart failure.
  • \<6 months.
  • Patients who are likely to be initiated on dialysis within the next 3 months per Investigator's assessment at the time of screening.
  • Previous bowel resection.
  • Coeliac disease.
  • Gastroenteritis in the 4 weeks prior to randomization.
  • Cognitive disabilities, physical or psychiatric disease that in the opinion of the Investigator/clinician influence the patient's adherence and successful completion of the study.

Prior/concomitant therapy:

  • Any treatment with roxadustat or a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHI).
  • Any red blood cells transfusion within 6 weeks prior to the first Screening Visit, or during the Screening Period.
  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within the 12 weeks prior to Screening Visit.
  • Exposure to IV iron or use of TRIFERIC® in dialysate during the Screening Period (ie, 2 weeks before randomization [Day 1]).
  • Exposure to iron-chelating agent (eg, deferoxamine/desferrioxamine, deferiprone or deferaxirox therapy) within the 6 weeks prior to the first Screening Visit.

Prior/concurrent clinical study experience:

  • Participation in any other clinical study that included drug treatment within at least 4 weeks of screening.

Other exclusions:

  • Involvement in the planning and/or conduct of the study (applies to AstraZeneca and FibroGen staff and/or staff at the study site).
  • Patient non-adherence to medications or missing >1 dialysis treatments/month per the Investigator's knowledge.
  • Previous randomization in the present study.
  • History of alcohol or drug abuse within 2 years prior to randomization.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Roxadustat

    Patients will receive oral dose of roxadustat three times a week (TIW) for 2- weeks during treatment period.

    Drug: Roxadustat

  • Active comparator
    rHuEPO

    Patients will receive uniform brand of short acting intravenous or subcutaneous dose of rHuEPO two times a week (BIW) or TIW based upon their previous dose of rHuEPO for 2- weeks during treatment period.

    Drug: rHuEPO

Interventions

  • The starting dose of roxadustat will be in accordance with the China package insert, and will depend on the body weight of the patient: 100 mg (45 to \< 60 kg) or 120 mg (≥ 60 kg) in patients on dialysis; 70 mg (40 to \< 60 kg) or 100 mg (≥ 60 kg) in non-dialysis patients.

  • DrugrHuEPO

    The starting dose of rHuEPO will be in accordance to the dosage approved in rHuEPO China package insert (patients on weekly dose of 6000 IU \[dosing will BIW\], and patients on weekly dose of \>6000 IU \[dosing will TIW\]) and on patient's haemoglobin levels.

06

What researchers measure

Primary outcomes

  1. Difference From Baseline to Day 15 in Area Under Curve (AUC) of GI Iron Absorption (0-3 Hours)

    The main effect of roxadustat versus rHuEPO on GI iron absorption was evaluated.

    Time frame: From Baseline (Day 1) to Day 15

Secondary outcomes

  1. Difference From Baseline to Day 15 in Area Under Curve (AUC) of Iron Absorption (0-3 Hours)

    The effect and interaction with key baseline variables of roxadustat versus rHuEPO on iron absorption was assessed.

    Time frame: From Baseline (Day 1) to Day 15

  2. Difference From Baseline to Day 15 in Serum Iron

    The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: serum iron was assessed.

    Time frame: From baseline (Day 1) to Day 15

  3. Difference From Baseline to Day 15 in Ferritin

    The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: Ferritin was assessed.

    Time frame: From baseline (Day 1) to Day 15

  4. Difference From Baseline to Day 15 in Total Iron Binding Capacity (TIBC)

    The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: TIBC was assessed.

    Time frame: From baseline (Day 1) to Day 15

  5. Relative Difference From Baseline to Day 15 in Transferrin Saturation (TSAT)

    The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: TSAT (fraction of TIBC) was assessed.

    Time frame: From baseline (Day 1) to Day 15

  6. Difference From Baseline to Day 15 in Transferrin

    The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: Transferrin was assessed.

    Time frame: From baseline (Day 1) to Day 15

  7. Difference From Baseline to Day 15 in Soluble Transferrin Receptor

    The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: Soluble transferrin receptor was assessed.

    Time frame: From baseline (Day 1) to Day 15

  8. Difference From Baseline to Day 15 in Hepcidin

    The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of Hepcidin was assessed.

    Time frame: From baseline (Day 1) to Day 15

  9. Number of Subjects With Adverse Events (AEs)

    AEs as variables of safety was assessed.

    Time frame: From screening (Starting on Day -21) until follow up (28 days) (approximately 7 weeks)

07

Results

Posted Apr 22, 2024
Limitations and caveats
* NDD randomization strata were merged because recruitment was insufficient. * The log-transform of AUC was removed from the primary assessment post-database-lock when negative AUC were discovered (which invalidated log-transformation).

Participant flow

The study was conducted in 25 subjects at 8 clinical sites in China, of which 5 sites enrolled patients from 17 March 2021 (first subject first randomized) to 12 October 2021 (last subject last visit).

Participant flow — Overall Study
MilestoneRoxadustatrHuEPO
Started1312
Completed1212
Not completed10
Withdrew: Failure to meet inclusion/exclusion criteria/ due to covid-19 pandemic10

Outcome measures

PrimaryDifference From Baseline to Day 15 in Area Under Curve (AUC) of GI Iron Absorption (0-3 Hours)

The main effect of roxadustat versus rHuEPO on GI iron absorption was evaluated.

Time frame:
From Baseline (Day 1) to Day 15
Reported as:
Mean · gram*3hours/deciliter (g*3hr/dL)
Difference From Baseline to Day 15 in Area Under Curve (AUC) of GI Iron Absorption (0-3 Hours)
gram*3hours/deciliter (g*3hr/dL)RoxadustatrHuEPO
Change from baseline11.288 ± 28.1506-0.259 ± 9.7369
Hemodialysis (HD) group- Change from baseline20.125 ± 29.9536-1.625 ± 10.2189
Peritoneal dialysis (PD)- Change from baseline-2.408 ± 19.4973-2.263 ± 6.7321
Non-dialysis-dependent (NDD)- Change from baseline34.700 ± 39.880815.950 ± NA
Statistical analysis
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.212 · Difference in estimate (lsm): 19.50 · 95% CI -11.155 to 50.150
SecondaryDifference From Baseline to Day 15 in Area Under Curve (AUC) of Iron Absorption (0-3 Hours)

The effect and interaction with key baseline variables of roxadustat versus rHuEPO on iron absorption was assessed.

Time frame:
From Baseline (Day 1) to Day 15
Reported as:
Mean · gram*3hours/deciliter (g*3hr/dL)
Difference From Baseline to Day 15 in Area Under Curve (AUC) of Iron Absorption (0-3 Hours)
gram*3hours/deciliter (g*3hr/dL)RoxadustatrHuEPO
Difference From Baseline to Day 15 in Area Under Curve (AUC) of Iron Absorption (0-3 Hours)11.288 ± 28.1506-0.259 ± 9.7369
Statistical analysis
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.441 · Difference in estimate: -0.13 · 95% CI -0.477 to 0.208
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.532 · Difference in estimates: -2.34 · 95% CI -9.707 to 5.017
SecondaryDifference From Baseline to Day 15 in Serum Iron

The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: serum iron was assessed.

Time frame:
From baseline (Day 1) to Day 15
Reported as:
Mean · micromole/Liter (µmol/L)
Difference From Baseline to Day 15 in Serum Iron
micromole/Liter (µmol/L)RoxadustatrHuEPO
Difference From Baseline to Day 15 in Serum Iron2.077 ± 7.9263-0.845 ± 7.6225
Statistical analysis
  • Roxadustat vs rHuEPO · Geometric ANCOVA · p = 0.688 · Ratio of estimates: 1.09 · 95% CI 0.723 to 1.635Geometric ANCOVA of relative change from baseline. The Standard error of Mean (SEM) refers to Geometric SEM.
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.029 · Difference in estimates: 0.43 · 95% CI 0.045 to 0.822
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.568 · Difference in estimates: 0.08 · 95% CI -0.201 to 0.366
SecondaryDifference From Baseline to Day 15 in Ferritin

The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: Ferritin was assessed.

Time frame:
From baseline (Day 1) to Day 15
Reported as:
Mean · microgram/Liter (µg/L)
Difference From Baseline to Day 15 in Ferritin
microgram/Liter (µg/L)RoxadustatrHuEPO
Difference From Baseline to Day 15 in Ferritin-49.354 ± 175.3039-43.536 ± 79.3449
Statistical analysis
  • Roxadustat vs rHuEPO · Geometric ANCOVA · p = 0.096 · Ratio of estimates: 0.84 · 95% CI 0.687 to 1.031Geometric ANCOVA of relative change from baseline. The Standard error of Mean (SEM) refers to Geometric SEM.
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.630 · Difference in estimates: -0.06 · 95% CI -0.282 to 0.171
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.015 · Difference in estimates: 0.19 · 95% CI 0.037 to 0.342
SecondaryDifference From Baseline to Day 15 in Total Iron Binding Capacity (TIBC)

The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: TIBC was assessed.

Time frame:
From baseline (Day 1) to Day 15
Reported as:
Mean · micromole/Liter (µmol/L)
Difference From Baseline to Day 15 in Total Iron Binding Capacity (TIBC)
micromole/Liter (µmol/L)RoxadustatrHuEPO
Difference From Baseline to Day 15 in Total Iron Binding Capacity (TIBC)8.638 ± 5.1118-0.490 ± 3.7784
Statistical analysis
  • Roxadustat vs rHuEPO · Geometric ANCOVA · p = < 0.001 · Ratio of estimates: 1.23 · 95% CI 1.123 to 1.354Geometric ANCOVA of relative change from baseline. The Standard error of Mean (SEM) refers to Geometric SEM.
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.171 · Difference in estimates: 0.06 · 95% CI -0.027 to 0.149
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.387 · Difference in estimates: 0.03 · 95% CI -0.039 to 0.101
SecondaryRelative Difference From Baseline to Day 15 in Transferrin Saturation (TSAT)

The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: TSAT (fraction of TIBC) was assessed.

Time frame:
From baseline (Day 1) to Day 15
Reported as:
Mean · Ratio
Relative Difference From Baseline to Day 15 in Transferrin Saturation (TSAT)
RatioRoxadustatrHuEPO
Relative Difference From Baseline to Day 15 in Transferrin Saturation (TSAT)-0.024 ± 0.1806-0.030 ± 0.2007
Statistical analysis
  • Roxadustat vs rHuEPO · Geometric ANCOVA · p = 0.561 · Ratio of estimates: 0.89 · 95% CI 0.606 to 1.312Geometric ANCOVA of relative change from baseline. The Standard error of Mean (SEM) refers to Geometric SEM.
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.043 · Difference in estimates: 0.38 · 95% CI 0.013 to 0.750
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.766 · Difference in estimates: 0.04 · 95% CI -0.222 to 0.302
SecondaryDifference From Baseline to Day 15 in Transferrin

The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: Transferrin was assessed.

Time frame:
From baseline (Day 1) to Day 15
Reported as:
Mean · gram/Liter (g/L)
Difference From Baseline to Day 15 in Transferrin
gram/Liter (g/L)RoxadustatrHuEPO
Difference From Baseline to Day 15 in Transferrin0.452 ± 0.3550-0.012 ± 0.1393
Statistical analysis
  • Roxadustat vs rHuEPO · Geometric ANCOVA · p = < 0.001 · Ratio of estimates: 1.23 · 95% CI 1.108 to 1.369Geometric ANCOVA of relative change from baseline. The Standard error of Mean (SEM) refers to Geometric SEM.
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.351 · Difference in estimates: 0.05 · 95% CI -0.059 to 0.159
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.248 · Difference in estimates: 0.04 · 95% CI -0.031 to 0.114
SecondaryDifference From Baseline to Day 15 in Soluble Transferrin Receptor

The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of iron metabolism: Soluble transferrin receptor was assessed.

Time frame:
From baseline (Day 1) to Day 15
Reported as:
Mean · milligram/Liter (mg/L)
Difference From Baseline to Day 15 in Soluble Transferrin Receptor
milligram/Liter (mg/L)RoxadustatrHuEPO
Difference From Baseline to Day 15 in Soluble Transferrin Receptor1.876 ± 3.06270.466 ± 0.5556
Statistical analysis
  • Roxadustat vs rHuEPO · Geometric ANCOVA · p = 0.021 · Ratio of estimates: 1.29 · 95% CI 1.043 to 1.598Geometric ANCOVA of relative change from baseline. The Standard error of Mean (SEM) refers to Geometric SEM.
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.826 · Difference in estimates: -0.03 · 95% CI -0.276 to 0.223
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.634 · Difference in estimates: -0.04 · 95% CI -0.212 to 0.132
SecondaryDifference From Baseline to Day 15 in Hepcidin

The effect and interaction with baseline variables of roxadustat versus rHuEPO on the indices of Hepcidin was assessed.

Time frame:
From baseline (Day 1) to Day 15
Reported as:
Mean · microgram/Liter (µg/L)
Difference From Baseline to Day 15 in Hepcidin
microgram/Liter (µg/L)RoxadustatrHuEPO
Difference From Baseline to Day 15 in Hepcidin-78.769 ± 87.9264-44.239 ± 88.2325
Statistical analysis
  • Roxadustat vs rHuEPO · Geometric ANCOVA · p = 0.007 · Ratio of estimates: 0.45 · 95% CI 0.257 to 0.786Geometric ANCOVA of relative change from baseline. The Standard error of Mean (SEM) refers to Geometric SEM.
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.610 · Difference in estimates: -0.16 · 95% CI -0.798 to 0.480
  • Roxadustat vs rHuEPO · ANCOVA · p = 0.740 · Difference in estimates: 0.07 · 95% CI -0.387 to 0.536
SecondaryNumber of Subjects With Adverse Events (AEs)

AEs as variables of safety was assessed.

Time frame:
From screening (Starting on Day -21) until follow up (28 days) (approximately 7 weeks)
Reported as:
Count of participants · Participants
Number of Subjects With Adverse Events (AEs)
ParticipantsRoxadustatrHuEPO
Any AE52
Any AE with outcome of death00
Any Serious Adverse event (SAE) (including events with outcome of death)00
Any AE leading to discontinuation of study treatment00
Any AE leading to dose interruption00
Any AE leading to dose reduction00
Any AE leading to dose escalation00
Any AE leading to withdrawal from study00
Any AE possibly related to study treatment10

Adverse events

Collected over From screening (Starting on Day -21) until follow up (28 days) (approximately 7 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roxadustat0/13 (0%)0/13 (0%)5/13 (38.5%)
rHuEPO0/12 (0%)0/12 (0%)2/12 (16.7%)
Most frequent other events
Most frequent other events
EventRoxadustatrHuEPO
HyperkalaemiaMetabolism and nutrition disorders1/132/12
Abdominal infectionInfections and infestations1/130/12
HypermagnesaemiaMetabolism and nutrition disorders1/130/12
SeizureNervous system disorders1/130/12
Open angle glaucomaEye disorders1/130/12
Back painMusculoskeletal and connective tissue disorders1/130/12
Muscle spasmsMusculoskeletal and connective tissue disorders1/130/12

Baseline characteristics

The Full analysis Set (FAS) was the primary efficacy analysis set and included all randomized patients who completed baseline (Day 1) measurements for any efficacy analysis.

Age, Continuous
Age, Continuous(Years)RoxadustatrHuEPOTotal
Mean57.3 ± 12.0952.8 ± 12.6455.1 ± 12.32
Age, Customized
Age, Customized(Participants)RoxadustatrHuEPOTotal
≥ 18 to < 50 years549
≥ 50 to < 65 years369
≥ 65 to < 75 years426
≥ 75 years101
Sex: Female, Male
Sex: Female, Male(Participants)RoxadustatrHuEPOTotal
Female9716
Male459
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RoxadustatrHuEPOTotal
Asian131225
08

Study locations

8 sites
  • Research Site
    Baotou, 14010, China
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100044, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Guangzhou, 510180, China
  • Research Site
    Jinan, 250012, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Wuhan, 430022, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Oct 2021, 7 months.

Results were first posted in Apr 2024, 2 years 6 months after primary completion.

Of 116 phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2020
First posted
Dec 4, 2020
StartActual
Feb 22, 2021
Primary completionActual
Oct 12, 2021
CompletionActual
Oct 12, 2021
Results first posted
Apr 22, 2024
Last update
Apr 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04655027
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Dec 4, 2020
Start date
Feb 22, 2021
Primary completion
Oct 12, 2021
Completion
Oct 12, 2021
Results posted
Apr 22, 2024
Last update
Apr 22, 2024

Study contacts

Li Xuemei
principal investigator · Peking Union Medical College Hospital (Dongdan campus) No.1 Shuaifuyuan Wangfujing Dongcheng District Beijing, China 100730

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion